The U.S. FDA approved Cablivi in combination with plasma exchange and immunosuppression for treating acquired thrombotic thrombocytopenic purpura (aTTP) in adults.

The French drugmaker Sanofi secured approval in Europe for a rare blood-clotting disorder treatment using nanobodies.

One week after Sanofi agreed to buy Waltham, Mass.-based Bioverativ for $11.6 billion, the French drugmaker announced the acquisition of Ghent, Belgium-based Ablynx for about $4.85 billion.

Ghent, Belgium-based Ablynx NV announced the price of its U.S. initial public offering (IPO) at $17.50.

Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder.